Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment
ConditionPeptic Ulcer Bleeding
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMario Steffanus
About this trial
The goal of this clinical trial is to compare the effects of tegoprazan vs lansoprazole in healing bleeding peptic ulcers. It will also teach about the safety of both modalities. The main questions it aims to answer are:
How does the effectiveness of Tegoprazan compare with Lansoprazole in two weeks of healing rate bleeding peptic ulcer patients in the Indonesian population?
Researchers will compare the drug tegoprazan to lansoprazole with a double-blind randomized control to see their effect on healing bleeding peptic ulcers.
Participants will:
Take drug tegoprazan 50 mg OD or lansoprazole 30 mg OD every day for 2 weeks Endoscopic examination at the beginning before treatment and after completion of treatment within 2 weeks Record of their adverse effect occurrence
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subjects diagnosed with upper gastrointestinal bleeding caused by peptic ulcer through gastroscopic examination
Disqualifiers
Allergic to Tegoprazan or Lansoprazole
Diagnosed with gastric or duodenal cancer, pregnant
History of H. pylori infection treatment failure
Presence of comorbidities such as chronic kidney disease or decompensated liver cirrhosis
Trial design
Design model
Parallel
Treatments tested in this trial
Tegoprazan
DrugTegoprazan 50 mg tab PO OD in 2 weeks
Lansoprazole
DrugLansoprazole 30 mg tab PO OD in 2 weeks
Treatment groups
162 Participants
are divided into 2 treatment groupsGroup A: Potassium Channel Acid BlockerExperimental treatment 1 intervention
Group B: Proton Pump InhibitorActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Healing Rate
The healing rate will be rated using Forrest Classification
Time frame
2 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Mario Steffanus
Lead sponsor
Dr Cipto Mangunkusumo General Hospital
Sponsor institution
Dr Cipto Mangunkusumo General Hospital
Collaborator
Source ClinicalTrials.gov